Kolexia
Borel Christian Oncologie médicale
Borel Christian
Oncologie médicale
Centre Paul Strauss
Strasbourg, France
94 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Carcinome épidermoïde de la tête et du cou Tumeurs de la tête et du cou Tumeurs colorectales Métastase tumorale Récidive tumorale locale Adénocarcinome Tumeurs du côlon

Collaborateurs

Voir plus
Ghiringhelli Francois
Ghiringhelli Francois
Centre Georges-François Leclerc, Dijon, France
Burgy Mickaël
Burgy Mickaël
Centre Paul Strauss, Strasbourg, France
Bennouna-Louridi Jaafar
Bennouna-Louridi Jaafar
Hôpital Foch, Suresnes, France
Guigay Joel
Guigay Joel
Centre Antoine Lacassagne, Nice, France

Industries

Voir plus
MSD
28 collaboration(s)
Dernière en 2023
Merck-Serono
15 collaboration(s)
Dernière en 2021
BMS
4 collaboration(s)
Dernière en 2020
Sanofi
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION): A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Essai Clinique (Emd Serono)   05 mars 2024
Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
BMC cancer   08 décembre 2023
HomeCareSIMEOX: Efficiency and Acceptability of SIMEOX® Used Autonomously at Home for Bronchial Clearance in Patients With Cystic Fibrosis: Prospective, Randomized Controlled Study
Essai Clinique (Physio-Assist)   15 novembre 2023
A novel ΔNp63-dependent immune mechanism improves prognosis of HPV-related head and neck cancer.
Frontiers in immunology   25 octobre 2023
752P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
923P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
IPRICE: Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
Essai Clinique (Institut de cancérologie Strasbourg Europe)   21 septembre 2023
i-tech PPC: Impact of Tele-visit Versus Home Visit by Home Care Provider on Compliance With Continuous Positive Airway Pressure (CPAP) Therapy of Patients With Obstructive Sleep Apnea Syndrome
Essai Clinique (Agir à Dom)   20 juillet 2023